Dermatomyositis Drug Market, by Drug Type (Corticosteroids, Immunosuppressive Agents, and Others), by Route of Administration (Oral, Topical, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (No

Dermatomyositis Drug Market, by Drug Type (Corticosteroids, Immunosuppressive Agents, and Others), by Route of Administration (Oral, Topical, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Dermatomyositis (DM) is a rare inflammatory muscle disease that affects both the muscles as well as the skin. Dermatomyositis can strike people of all races, genders, and ages. Although, both males and females are affected equally in childhood, it is more common in females in adults. The exact cause of DM is unknown but it is believed to result from an immune-mediated process triggered by outside factors (e.g. malignancy, drugs, and infectious Drug Types) in genetically predisposed individuals. Dermatomyositis can occur with other connective tissue disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, and mixed connective tissue disease.

Market Dynamics

Key players operating in the global dermatomyositis drug market are focusing on adoption of growth strategies such as product approvals which is expected to drive the market growth during the forecast period. For instance, in July 2018, Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Moreover, increasing research and development activities by key players for the treatment of dermatomyositis which is expected to drive the market growth over the forecast period. For instance, on October 21, 2019, CSL Behring,a biopharmaceutical company initiated phase 3 Study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in adults with dermatomyositis (DM). The study is estimated to be completed in February 2024.

Key features of the study:

• This report provides an in-depth analysis of the global dermatomyositis drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dermatomyositis drug market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, Asahi Kasei Corporation., Octapharma USA, Healthcare Pharmaceuticals Limited., Zydus Cadila, Alkem Laboratories Ltd, Apotex Inc, Eli Lilly and Co, and F.Hoffman-La Roche Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dermatomyositis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis drug market

Detailed Segmentation:

• Global Dermatomyositis Drug Market, By Drug Type:
• Corticosteroids
• Immunosuppressive Agents
• Others
• Global Dermatomyositis Drug Market, By Route of Administration:
• Oral
• Topical
• Others
• Global Dermatomyositis Drug Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Global Dermatomyositis Drug Market, By Region:
• North America

By Country

• U.S.
• Canada
• Latin America

By Country

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe

By Country

• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific

By Country

• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East

By Country

• GCC
• Israel
• Rest of Middle East
• Africa

By Country

• South Africa
• Central Africa
• North Africa
• Company Profiles
• Pfizer Inc *

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

• Teva Pharmaceuticals USA, Inc.
• Hikma Pharmaceuticals PLC
• Asahi Kasei Corporation
• Octapharma USA
• Healthcare Pharmaceuticals Limited
• Zydus Cadila
• Alkem Laboratories Ltd
• Apotex Inc
• Eli Lilly and Co
• F.Hoffman-La Roche Ltd

“*” marked represents similar segmentation in other categories in the respective section.